Pharmacology of Streptokinase

Introduction/Overview

Streptokinase represents a cornerstone agent in the pharmacological management of acute thrombotic occlusions. Derived from β-hemolytic streptococci, this protein functions as an indirect activator of the fibrinolytic system, converting plasminogen to plasmin. Its introduction revolutionized the treatment of acute myocardial infarction, establishing the principle that timely coronary reperfusion could salvage ischemic myocardium and reduce mortality. The clinical relevance of streptokinase persists, particularly in resource-limited settings, due to its significant cost advantage compared to newer fibrin-specific agents. However, its use is accompanied by a distinct pharmacological profile, including antigenicity and a systemic fibrinolytic state, which necessitates careful patient selection and monitoring.

The importance of understanding streptokinase pharmacology extends beyond its direct clinical application. It serves as a prototypical model for understanding the fundamental principles of thrombolysis, the balance between therapeutic clot dissolution and hemorrhagic risk, and the challenges associated with biologic agents derived from bacterial sources. Mastery of its properties allows clinicians to make informed decisions regarding its appropriate use within the broader therapeutic arsenal for cardiovascular and thromboembolic diseases.

Learning Objectives

• Describe the biochemical origin and classification of streptokinase as an indirect, non-fibrin-specific plasminogen activator.
• Explain the detailed molecular mechanism by which streptokinase forms a complex with plasminogen to catalyze the conversion of other plasminogen molecules to plasmin.
• Analyze the pharmacokinetic profile of streptokinase, including its biphasic elimination, and relate this to dosing regimens for different clinical indications.
• Evaluate the approved therapeutic indications for streptokinase, contrasting its use with alternative thrombolytics based on efficacy and safety profiles.
• Identify the major adverse effects, contraindications, and drug interactions associated with streptokinase therapy, with particular emphasis on bleeding risk and antigenic reactions.

Classification

Streptokinase is systematically classified within the broader category of thrombolytic (fibrinolytic) agents. These drugs are designed to lyse pathological thrombi by accelerating the conversion of plasminogen to the proteolytic enzyme plasmin.

Therapeutic Classification

Within therapeutic classifications, streptokinase is defined as a thrombolytic drug or fibrinolytic agent. It is further characterized as a first-generation thrombolytic, distinguishing it from later-developed, fibrin-specific agents like alteplase (t-PA) and tenecteplase. Its first-generation status is primarily due to its mechanism, which induces a systemic lytic state rather than acting preferentially at the site of the thrombus.

Mechanistic Classification

Mechanistically, streptokinase is an indirect plasminogen activator. Unlike direct activators such as urokinase, streptokinase itself possesses no intrinsic enzymatic activity. It must first form a stoichiometric 1:1 complex with plasminogen (or plasmin) to create an active site capable of converting additional free plasminogen molecules to plasmin. This complex is referred to as streptokinase-plasminogen activator complex.

Chemical and Biological Classification

Chemically, streptokinase is a non-enzymatic, single-chain polypeptide protein with a molecular weight of approximately 47 kDa. It is composed of 414 amino acids. Biologically, it is a bacterial exoprotein originally isolated from Lancefield group C β-hemolytic Streptococcus equisimilis. It is produced commercially using recombinant DNA technology in suitable bacterial hosts, which ensures purity and reduces batch-to-bariable potency. It is not a human protein, which is the fundamental basis for its antigenic properties.

Mechanism of Action

The mechanism of action of streptokinase is a multi-step process that results in the widespread degradation of fibrin clots, fibrinogen, and other plasma proteins. Its action is indirect and systemic, contrasting with the fibrin-selective mechanisms of tissue-type plasminogen activator (t-PA).

Molecular and Biochemical Basis

Streptokinase does not cleave plasminogen directly. The initial step involves the formation of a high-affinity, non-covalent complex between one molecule of streptokinase and one molecule of human plasminogen. This binding induces a conformational change in the plasminogen molecule, unmasking an active site within its serine protease domain. The newly formed streptokinase-plasminogen complex, while not yet proteolytically active on fibrin, now functions as a potent activator of other free plasminogen molecules.

This activator complex catalyzes the cleavage of a specific Arg⁵⁶⁰-Val⁵⁶¹ peptide bond in free plasminogen, converting it into the active enzyme plasmin. Plasmin is a serine protease with broad substrate specificity. Its primary physiological target is fibrin, the insoluble meshwork of a thrombus. Plasmin degrades fibrin into soluble fibrin degradation products (FDPs) or D-dimers, leading to thrombus dissolution.

Systemic Fibrinolytic State

A critical consequence of streptokinase’s mechanism is the induction of a systemic fibrinolytic state. Because the activator complex is not fibrin-bound, it catalyzes the conversion of plasminogen to plasmin throughout the circulation. This results in the generation of substantial amounts of free, circulating plasmin. This systemic plasmin exerts several effects:

• Degradation of fibrinogen (fibrinogenolysis): Circulating plasmin cleaves fibrinogen into non-functional fragments (Fragments X, Y, D, and E), leading to a reduction in plasma fibrinogen levels, often by 50-90% during therapy.
• Degradation of other clotting factors: Factors V and VIII are particularly susceptible to proteolysis by plasmin, contributing to a coagulopathic state.
• Generation of fibrin(ogen) degradation products (FDPs): These fragments, particularly the high-molecular-weight ones, exhibit anticoagulant properties by inhibiting platelet aggregation and fibrin polymerization.

The combined effect of hypofibrinogenemia, depletion of clotting factors, and circulating anticoagulant FDPs creates a profound systemic anticoagulant and lytic environment. This is both the source of its therapeutic effect (lysis of distant, non-targeted microthrombi may be beneficial) and its primary toxicity (increased risk of hemorrhage).

Comparison with Fibrin-Specific Agents

The mechanism contrasts sharply with fibrin-specific agents like alteplase. Tissue-type plasminogen activator has a high affinity for fibrin and activates plasminogen primarily when both are bound to the fibrin surface, leading to localized fibrinolysis with less systemic plasmin generation and fibrinogen depletion. Streptokinase’s non-fibrin-specific, systemic action is a key differentiator in its pharmacological profile.

Pharmacokinetics

The pharmacokinetics of streptokinase are complex due to its protein nature, its mechanism of action through complex formation, and the influence of neutralizing antibodies. Its pharmacokinetic parameters are best described in terms of its functional activity in plasma rather than its plasma concentration per se.

Absorption

Streptokinase is not administered orally due to extensive proteolytic degradation in the gastrointestinal tract. It is administered exclusively by the intravenous or, less commonly, intracoronary route. Following intravenous infusion, the drug is immediately and completely bioavailable within the systemic circulation. Intramuscular administration is contraindicated due to the high risk of hematoma formation at the injection site.

Distribution

The volume of distribution of streptokinase is approximately equal to the plasma volume (3-6 L in adults), suggesting limited extravascular distribution. It distributes rapidly throughout the intravascular compartment. The streptokinase-plasminogen activator complex, however, can diffuse into the interstitium and has been detected in lymphatic fluid. Its large molecular size and protein nature restrict its passage across the blood-brain barrier under normal conditions, although this may be altered in pathological states.

Metabolism and Elimination

Streptokinase is eliminated via a biphasic process. The initial, rapid clearance phase is mediated primarily by the formation of neutralizing antibodies and immune complex formation. The streptokinase-plasminogen activator complex and free streptokinase are cleared by the reticuloendothelial system, predominantly in the liver and spleen. Proteolytic degradation also contributes to its elimination.

A significant pharmacokinetic consideration is the presence of neutralizing anti-streptokinase antibodies in patients with prior streptococcal exposure. These antibodies can rapidly inactivate the drug, reducing its effective concentration and thrombolytic efficacy. Antibody titers typically rise 3-5 days after administration and can remain elevated for 6 months to several years, rendering repeat administration ineffective and potentially hazardous due to risk of allergic reactions.

Half-Life and Pharmacokinetic Parameters

The functional half-life of streptokinase is derived from the decay of fibrinolytic activity in plasma. The half-life of the streptokinase-plasminogen activator complex is approximately 23 minutes (often reported as 18-30 minutes). However, the biological effects of the therapy, particularly the depletion of fibrinogen and clotting factors, persist for much longer—often 12 to 24 hours after discontinuation of the infusion—because these proteins must be resynthesized by the liver.

Clearance is predominantly saturable and follows Michaelis-Menten kinetics at therapeutic concentrations. The relationship between dose, plasma activity, and therapeutic effect is not linear. Standard dosing regimens are therefore empirically derived to achieve and maintain a systemic lytic state for a duration sufficient to achieve coronary or vascular recanalization.

Dosing Considerations

Dosing is based on established protocols for specific indications and is not weight-based in adults, unlike some newer thrombolytics. For acute myocardial infarction, a common regimen involves an intravenous loading dose of 1.5 million IU infused over 60 minutes. For pulmonary embolism, a similar or slightly higher dose (e.g., 3 million IU over 24 hours) may be used. The fixed-dose strategy accounts for the complex pharmacokinetics and the goal of achieving a predictable level of systemic fibrinolysis. Dose adjustment for renal or hepatic impairment is not standardly recommended, as the drug is cleared immunologically and by the reticuloendothelial system; however, the bleeding risk in such patients is heightened due to comorbid factors.

Therapeutic Uses/Clinical Applications

The therapeutic application of streptokinase is centered on the rapid dissolution of acute, pathological thrombi to restore blood flow and prevent tissue necrosis. Its use has been largely supplanted by fibrin-specific agents and percutaneous coronary intervention (PCI) in many high-resource settings, but it retains significant global importance.

Approved Indications

1. Acute ST-Elevation Myocardial Infarction (STEMI): This was the landmark indication for streptokinase. When administered within 12 hours (ideally within 3-4 hours) of symptom onset, it reduces mortality, limits infarct size, and preserves left ventricular function. Its efficacy is time-dependent, with greatest benefit when given early. In settings where primary PCI cannot be performed within 120 minutes of first medical contact, streptokinase remains a recommended thrombolytic option, particularly when cost is a major constraint.

2. Acute Massive Pulmonary Embolism (PE): Streptokinase is indicated for the lysis of acute, extensive pulmonary emboli associated with hemodynamic instability (e.g., hypotension, shock). It can rapidly reduce pulmonary artery pressure and improve right ventricular function by dissolving the obstructive embolic material. Protocols often involve a prolonged infusion (e.g., 250,000 IU over 30 minutes, then 100,000 IU/hour for 12-72 hours).

3. Deep Vein Thrombosis (DVT): It may be used in the management of acute, extensive proximal DVT (e.g., iliofemoral thrombosis) to prevent the post-thrombotic syndrome. This use is less common due to the bleeding risk and the effectiveness of anticoagulation alone, but it may be considered in selected cases with severe symptoms and low bleeding risk.

4. Arterial Thrombosis and Embolism: Intra-arterial infusion of streptokinase can be used for acute peripheral arterial occlusion, though this has been largely replaced by catheter-directed thrombolysis with other agents or mechanical thrombectomy.

5. Occluded Access Devices: Streptokinase is sometimes used to clear thrombi from occluded central venous catheters or arteriovenous shunts, typically using a small volume instilled into the device and left to dwell.

Off-Label Uses

Historically, streptokinase was investigated for use in acute ischemic stroke. However, it was found to be associated with an unacceptably high risk of intracranial hemorrhage and worse outcomes compared to placebo, leading to its abandonment for this indication. It is absolutely contraindicated in stroke. Its use in other thrombotic conditions, such as prosthetic valve thrombosis, has been described but is not a standard approved indication and requires highly specialized management.

Adverse Effects

The adverse effect profile of streptokinase is dominated by hemorrhage and immunological reactions, direct consequences of its mechanism of action and bacterial origin.

Common Side Effects

• Bleeding: The most frequent complication, occurring in 5-20% of patients. This is most commonly minor bleeding from vascular puncture sites, gingival oozing, or superficial bruising. It is a direct result of the systemic fibrinolytic state, characterized by hypofibrinogenemia and elevated FDPs.
• Hypotension: A relatively common occurrence, particularly during the initial infusion. The mechanism may involve bradykinin generation (via plasmin-mediated activation of kallikrein) or vasodilation secondary to allergic reactions. It is often manageable by slowing or temporarily halting the infusion and administering intravenous fluids.
• Allergic Reactions: Mild reactions such as urticaria, pruritus, and flushing occur in 1-5% of patients. These are mediated by IgE or IgG antibodies and are generally manageable with antihistamines and corticosteroids.

Serious and Rare Adverse Reactions

• Major Hemorrhage: Defined as intracranial hemorrhage (ICH), retroperitoneal bleeding, or bleeding requiring transfusion or causing hemodynamic compromise. The risk of ICH is approximately 0.3-0.5%. Risk factors include advanced age, low body weight, hypertension on presentation, and concomitant use of anticoagulants.
• Anaphylaxis and Severe Allergic Reactions: Although rare (less than 0.1%), severe anaphylactoid or anaphylactic reactions, including bronchospasm, angioedema, and circulatory collapse, can occur, especially with rapid re-administration (within 6 months to 5 years of prior exposure).
• Reperfusion Arrhythmias: Following successful coronary thrombolysis, transient arrhythmias such as accelerated idioventricular rhythm or ventricular ectopy are common and are considered a marker of reperfusion. They are usually self-limiting but require monitoring.
• Fever and Chills: A pyrogenic response, often mild, occurs in a significant minority of patients and may be related to cytokine release.

Black Box Warnings and Major Risks

Streptokinase carries a Black Box Warning, the strongest safety alert mandated by regulatory agencies. The warning highlights several life-threatening risks:

1. Bleeding: The drug can cause serious and potentially fatal hemorrhage, including intracranial, retroperitoneal, gastrointestinal, and genitourinary bleeding. It is contraindicated in patients with active internal bleeding, history of hemorrhagic stroke, or recent intracranial/intraspinal surgery.
2. Arterial Embolism: Lysis of thrombi on the left side of the heart in patients with atrial fibrillation or mitral stenosis may dislodge and cause systemic embolization.
3. Allergic Reactions: Severe anaphylactic reactions can occur. Patients with recent streptococcal infection or prior streptokinase exposure (within 6 months to several years) are at increased risk.
4. Re-administistration: Administration after a previous dose is associated with reduced efficacy and increased risk of allergic reactions due to neutralizing antibodies. Re-administration should generally be avoided after 5 days from initial exposure and is not recommended within 6 months to 2 years.

Drug Interactions

The concomitant use of streptokinase with other drugs that affect hemostasis significantly amplifies the risk of hemorrhage. Management of these interactions requires careful timing and dose adjustment.

Major Drug-Drug Interactions

Anticoagulants (Heparin, Warfarin, Direct Oral Anticoagulants – DOACs): Concomitant use markedly increases bleeding risk. In STEMI protocols, intravenous unfractionated heparin is often administered after the streptokinase infusion is complete (e.g., after 4-6 hours) and when the activated partial thromboplastin time (aPTT) falls below twice the upper limit of normal, to prevent re-occlusion. Concurrent initiation is avoided. Warfarin and DOACs are typically withheld prior to thrombolysis.

Antiplatelet Agents: Aspirin is routinely co-administered with streptokinase for acute MI and has been shown to provide additive mortality benefit. However, the combination of streptokinase with more potent antiplatelet regimens (e.g., dual therapy with aspirin and a P2Y₁₂ inhibitor like clopidogrel) or glycoprotein IIb/IIIa inhibitors is associated with a substantially higher risk of major bleeding and is generally contraindicated.

Other Thrombolytics: Concurrent administration with other fibrinolytic agents offers no therapeutic advantage and drastically increases the risk of life-threatening hemorrhage.

Drugs Affecting Platelet Function: Nonsteroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) may increase the risk of bleeding when used with streptokinase.

Contraindications

Contraindications to streptokinase therapy are absolute and relative, primarily focusing on bleeding risk and antigenic exposure.

Absolute Contraindications:

• Any prior intracranial hemorrhage.
• Known structural cerebral vascular lesion (e.g., arteriovenous malformation).
• Known malignant intracranial neoplasm.
• Ischemic stroke within 3 months (except acute ischemic stroke within 4.5 hours, for which it is not used).
• Suspected aortic dissection.
• Active bleeding or bleeding diathesis (excluding menses).
• Significant closed-head or facial trauma within 3 months.
• Intracranial or intraspinal surgery within 2 months.
• Severe uncontrolled hypertension unresponsive to emergency therapy.
• Prior allergic reaction to streptokinase.
• Previous treatment with streptokinase within the prior 6 months to 2 years.

Relative Contraindications: These require careful risk-benefit assessment and include:

• History of chronic, severe, poorly controlled hypertension.
• Major surgery, biopsy of a parenchymal organ, or serious trauma within 4 weeks.
• Recent (within 2-4 weeks) internal bleeding.
• Noncompressible vascular punctures.
• Pregnancy and first week postpartum.
• Active peptic ulcer disease.
• Oral anticoagulant therapy.
• Advanced age (e.g., >75 years).

Special Considerations

The use of streptokinase in specific patient populations requires modification of the standard risk-benefit calculus due to altered physiology, increased vulnerability, or lack of robust clinical data.

Pregnancy and Lactation

Pregnancy: Streptokinase is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. While the large molecular size suggests limited placental transfer, the drug can induce a systemic lytic state in the mother, posing a significant risk of uterine bleeding, placental abruption, and fetal loss. Its use is generally reserved for life-threatening maternal conditions, such as massive pulmonary embolism with hemodynamic compromise, where the potential benefit justifies the potential fetal risk.

Lactation: It is not known whether streptokinase is excreted in human milk. Given its large protein size, excretion is considered unlikely. However, because of the potential for serious adverse reactions in nursing infants from a systemic lytic state, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Considerations

The safety and efficacy of streptokinase in pediatric patients have not been established through large randomized trials. Its use is generally limited to rare, life-threatening thrombotic conditions, such as massive pulmonary embolism or thrombosis of prosthetic heart valves. Dosing in children is not standardized and is often based on small case series, typically using regimens such as 3,500-4,000 IU/kg as a loading dose followed by a maintenance infusion. Monitoring for bleeding and allergic reactions is critical.

Geriatric Considerations

Patients over the age of 75 are at significantly increased risk of intracranial hemorrhage and major bleeding complications with thrombolytic therapy. This increased risk is due to a higher prevalence of cerebrovascular disease, cerebral amyloid angiopathy, age-related changes in the cerebral vasculature, and comorbid conditions. While not an absolute contraindication, the decision to use streptokinase in elderly patients requires extremely careful individual assessment of the bleeding risk versus the potential benefit of reperfusion. Some guidelines suggest a preference for primary PCI over thrombolysis in this population when feasible.

Renal and Hepatic Impairment

Renal Impairment: Streptokinase is not primarily renally excreted, and dose adjustment for renal dysfunction is not required. However, patients with renal failure often have concomitant platelet dysfunction and are at a higher baseline risk of bleeding. Furthermore, they may have altered volumes of distribution. Careful monitoring of coagulation parameters and bleeding signs is essential.

Hepatic Impairment: The liver is a site of clearance for the streptokinase-plasminogen complex and is responsible for synthesizing fibrinogen and clotting factors. Severe hepatic impairment may theoretically prolong the biological effects of streptokinase due to impaired synthesis of clotting factors, potentially exacerbating and prolonging the coagulopathy. No specific dose adjustments are recommended, but heightened vigilance for bleeding is warranted.

Summary/Key Points

Streptokinase is a first-generation, indirect plasminogen activator with a distinct pharmacological profile that continues to hold clinical relevance in specific contexts.

Bullet Point Summary

• Streptokinase is a bacterial protein that forms a 1:1 complex with plasminogen, creating an activator that converts additional plasminogen to plasmin.
• Its mechanism induces a systemic fibrinolytic state, characterized by depletion of fibrinogen, Factors V and VIII, and generation of anticoagulant fibrin(ogen) degradation products.
• Pharmacokinetically, it has a functional half-life of ~23 minutes but its biological effects on coagulation persist for 12-24 hours. Clearance is influenced by neutralizing antibodies.
• Primary indications include acute STEMI (where primary PCI is not available), massive pulmonary embolism, and extensive DVT.
• The most significant adverse effects are hemorrhage (minor and major, including intracranial) and allergic reactions due to its antigenicity.
• It carries a Black Box Warning for bleeding, arterial embolism, allergic reactions, and risks associated with re-administration.
• Major drug interactions involve concurrent use of anticoagulants and potent antiplatelet agents, which dramatically increase bleeding risk.
• Use in pregnancy, pediatrics, and the elderly requires extreme caution due to elevated risks.

Clinical Pearls

• Streptokinase should not be re-administered between 5 days and 2 years after a previous dose due to neutralizing antibodies and allergy risk.
• Hypotension during infusion is common; it can often be managed by slowing the infusion rate and does not always require permanent discontinuation.
• Concomitant heparin should typically be delayed until several hours after the streptokinase infusion is complete and the aPTT has normalized, to avoid synergistic bleeding.
• The benefit of thrombolysis for STEMI is profoundly time-dependent; “time is muscle.” The decision to use streptokinase must be weighed against the availability and delay to primary PCI.
• Monitoring during therapy should include frequent checks for bleeding, blood pressure, heart rate, and, if available, fibrinogen levels and FDPs.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.